Q-omics provides the consensus-scored TMSB4XP2 profile across patient tissues and cancer cell-line models. TMSB4XP2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TMSB4XP2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, TMSB4XP2 RNA expression shows 10,810 significant gene co-expression associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, THCA, and GBM as cancer lineages where TMSB4XP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMSB4XP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMSB4XP2 survival associations across molecular data types. TMSB4XP2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMSB4XP2 RNA expression–survival associations across cancer types. High TMSB4XP2 expression shows unfavorable associations in STAD, LGG and KIRP, but favorable associations in SKCM, KIRC and READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for TMSB4XP2 RNA expression.
This table summarizes TMSB4XP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMSB4XP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMSB4XP2 shows lower tumor expression in LUSC and higher tumor expression in THCA, KIRC, HNSC and LIHC. The THCA box plot shows higher TMSB4XP2 RNA expression in tumor versus normal tissue (log2 FC = +0.964, t-test p < 0.001).
This table shows molecular features associated with TMSB4XP2 in patient tissues and cancer cell lines. In patient samples, TMSB4XP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
